Copyright
©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 1047-1063
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1047
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1047
Table 3 Radiological response, n (%)
| RTCh | Ch | P value | |
| (n = 40) | (n = 27) | ||
| Disease progression | 1 (2.5) | 4 (14.8) | 0.025 |
| Stable disease | 14 (35) | 14 (51.9) | |
| Partial response | 25 (62.5) | 8 (29.6) | |
| Complete response | 0 | 1 (3.7) |
- Citation: Muñoz-Guglielmetti D, Sanchez-Lorente D, Reyes R, Martinez D, Lucena C, Boada M, Paredes P, Parera-Roig M, Vollmer I, Mases J, Martin-Deleon R, Castillo S, Benegas M, Muñoz S, Mayoral M, Cases C, Mollà M, Casas F. Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations. World J Clin Oncol 2021; 12(11): 1047-1063
- URL: https://www.wjgnet.com/2218-4333/full/v12/i11/1047.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i11.1047